Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Atyr Pharma Inc (LIFE)

Atyr Pharma Inc (LIFE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 35,749
  • Shares Outstanding, K 10,185
  • Annual Sales, $ 420 K
  • Annual Income, $ -23,600 K
  • 60-Month Beta 1.97
  • Price/Sales 84.71
  • Price/Cash Flow N/A
  • Price/Book 1.04
Trade LIFE with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.80
  • Number of Estimates 3
  • High Estimate -0.68
  • Low Estimate -0.94
  • Prior Year -1.54
  • Growth Rate Est. (year over year) +48.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.93 +24.50%
on 10/28/20
3.72 -1.94%
on 11/25/20
+0.34 (+10.21%)
since 10/23/20
3-Month
2.93 +24.50%
on 10/28/20
4.40 -17.10%
on 09/16/20
-0.66 (-15.36%)
since 08/25/20
52-Week
2.13 +71.26%
on 03/19/20
7.62 -52.13%
on 01/06/20
-0.60 (-14.17%)
since 11/25/19

Most Recent Stories

More News
Heart Valve Repair and Replacement Market Share | Growth, Opportunities, Industry Applications, Analysis and Forecast To 2025

AORTF : 4.6730 (+3.33%)
BSX : 33.66 (-0.38%)
CRY : 21.10 (-2.36%)
LIFE : 3.65 (+3.99%)
MDT : 113.92 (-0.12%)
NVCN.TO : 1.04 (-7.14%)
STJ : 80.82 (+0.16%)
Prosthetic Heart Valve Market Research Report by Type, by Sensor, by Technology, by End-use Industry – Global Forecast to 2025 – Cumulative Impact of COVID-19

The Global is expected to exceed more than USD$ 4 Billion by 2024; Growing at a CAGR of more than 9% in the given forecast period.

ABT : 105.96 (-1.53%)
BSX : 33.66 (-0.38%)
CRY : 21.10 (-2.36%)
EW : 84.46 (-1.34%)
LIFE : 3.65 (+3.99%)
NVCN.TO : 1.04 (-7.14%)
STJ : 80.82 (+0.16%)
Atyr Pharma: 3Q Earnings Snapshot

SAN DIEGO (AP) _ Atyr Pharma Inc. (LIFE) on Thursday reported a loss of $6.6 million in its third quarter.

LIFE : 3.65 (+3.99%)
aTyr Pharma Announces Third Quarter 2020 Results and Provides Corporate Update

Completes enrollment of ATYR1923 clinical trial in patients with COVID-19 severe respiratory complications. Topline data is expected at turn of calendar year.

LIFE : 3.65 (+3.99%)
aTyr Pharma, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / November 12, 2020 / aTyr Pharma, Inc. (NASDAQ:LIFE) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on November 12, 2020 at 5:00...

LIFE : 3.65 (+3.99%)
aTyr Pharma Announces Publication in the Journal mAbs

Peer-reviewed paper supports aTyr's antibody program.

LIFE : 3.65 (+3.99%)
aTyr Pharma Announces Discovery of New Receptor Targets for Two tRNA Synthetases from its Pipeline

Discovery advances the understanding of extracellular tRNA synthetase pathways.

LIFE : 3.65 (+3.99%)
Cardiovascular Implants Market Report 2020, Industry Trends, Size, Share, Growth and Forecast to 2025

According to a new report by IMARC Group, the size was worth US$ 20.8 Billion in 2019. Looking forward, the market is expected to continue its moderate growth during the next five years.

ABT : 105.96 (-1.53%)
BSX : 33.66 (-0.38%)
LIFE : 3.65 (+3.99%)
MDT : 113.92 (-0.12%)
NVCN.TO : 1.04 (-7.14%)
Atyr Pharma (LIFE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Atyr Pharma (LIFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LIFE : 3.65 (+3.99%)
aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2020 Financial Results - Management to host conference call and webcast on November 12th at 5:00 pm EST / 2:00 pm PST

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will report third...

LIFE : 3.65 (+3.99%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr Pharma, Inc. is a based in SAN DIEGO, United States.

See More

Key Turning Points

2nd Resistance Point 3.69
1st Resistance Point 3.60
Last Price 3.65
1st Support Level 3.42
2nd Support Level 3.33

See More

52-Week High 7.62
Fibonacci 61.8% 5.52
Fibonacci 50% 4.88
Fibonacci 38.2% 4.23
Last Price 3.65
52-Week Low 2.13

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar